相关实验视频

Updated: May 2, 2026

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

RFX1调节免疫微环境,并预测结肠癌中的免疫疗法反应:一个多方体和临床分析

Zhujiang Dai^1,2, Xiaoyong Ge^1,2, Wenbo Tang^1,2

¹Department of Colorectal Surgery, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200092, China.

Oncology research

|December 22, 2025

概括

调节因子X1 (RFX1) 表达,结合持续的瘤突变负担 (pTMB),预测结肠癌的预后. 高水平的RFX1和pTMB表明前景不佳,而低水平则表明预后更好.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
癌症基因组学癌症基因组学

背景情况:

调节因子X1 (RFX1) 在结肠癌进展中的作用及其对瘤微环境的影响尚不清楚.
澄清RFX1的分子和临床意义对于推进结肠癌治疗策略至关重要.

研究的目的:

阐明RFX1在结肠癌中的分子和临床作用.
调查RFX1表达的预测价值与瘤突变负担 (TMB) 和持续瘤突变负担 (pTMB) 结合用于患者预后.

主要方法:

结肠癌被分为高和低RFX1表达子组.
分析了免疫,突变和药物敏感性概况.
开发并验证了整合RFX1表达和pTMB的nomogram临床预测模型.

主要成果:

持续性瘤突变负担 (pTMB) 是一个比瘤突变负担 (TMB) 更敏感的预后预测因素.
与RFX1和TMB相比,RFX1表达和pTMB的组合显示出更高的预测效率.
患有高RFX1/高pTMB患者的生存率最差,而患有低RFX1/低pTMB患者的预后更好 (p < 0.0001).
高RFX1表达独立地与增加结肠癌风险相关 (HR=1.52,p=0.031).

结论:

结合RFX1和pTMB的诺姆图模型为结肠癌诊断和治疗提供了一种新的方法.
这个模型可以帮助分层患者并指导治疗决策.

关键词:

结肠癌是什么意思结肠癌是什么意思胰腺癌是一种癌症.持续的瘤突变负担突变负担监管工厂 X1 监管工厂 X1 瘤微环境是一个微环境.

更多相关视频

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

Author Spotlight: Multiplex Immunofluorescence Combined with Spatial Image Analysis for the Clinical and Biological Assessment of the Tumor Microenvironment

Author Spotlight: Multiplex Immunofluorescence Combined with Spatial Image Analysis for the Clinical and Biological Assessment of the Tumor Microenvironment

Published on: June 2, 2023

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...